Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Silsbee who wrote (54)	1/3/1997 6:34:00 PM
From: scaram(o)uche	of 1494

This is what I said on the 24th....... "Something's going to give soon. I can feel it. CRF and/or memantine. As clumsy as Price has been, NTII is still sitting on projects that have not been sufficiently scrutinized. $26 million for CRF, dynorphin, memantine, and the second generation NMDAR antagonists from Lipton's lab is _absurd_." When I first invested in NTII, I thought that CRF was worthless. I was apparently correct. I got sucked up in the last clinical data, and began to think that CRF might contribute as an adjunct therapy for RA. I should have stuck with my initial impression. But, while I am remarkably ticked at Price, I still think that he's sitting on good projects. Cheers! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next